http://hl7.eu/fhir/ig/gravitate-health/Bundle/bundlepackageleaflet-en-a38f06714db0c27b2ba704652e3f08c5
type: Bundle
node role: treeRoot
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi
    l: Bundle-uv-epi
language:
  v: en
identifier:
  system:
    v: https://www.gravitatehealth.eu/sid/doc
    l: doc
type:
  v: document
timestamp:
  v: 2023-06-27T10:09:22Z
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/Composition/composition-en-d33868162d255ced115cecbbf188aab4
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-humalog-glycerol
    l: ingredient-for-humalog-glycerol
  resource: ingredient-for-humalog-glycerol
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-humalog-hydrochloricacid
    l: ingredient-for-humalog-hydrochloricacid
  resource: ingredient-for-humalog-hydrochloricacid
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-humalog-sodiumhydroxide
    l: ingredient-for-humalog-sodiumhydroxide
  resource: ingredient-for-humalog-sodiumhydroxide
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-humalog-sterilewaterforinjection
    l: ingredient-for-humalog-sterilewaterforinjection
  resource: ingredient-for-humalog-sterilewaterforinjection
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-humalog-insulinlispro
    l: ingredient-for-humalog-insulinlispro
  resource: ingredient-for-humalog-insulinlispro
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-humalog-zincoxide
    l: ingredient-for-humalog-zincoxide
  resource: ingredient-for-humalog-zincoxide
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-humalog-metacresol
    l: ingredient-for-humalog-metacresol
  resource: ingredient-for-humalog-metacresol
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-humalog-trometamol
    l: ingredient-for-humalog-trometamol
  resource: ingredient-for-humalog-trometamol
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/SubstanceDefinition/substance-insulinlispro
    l: substance-insulinlispro
  resource: substance-insulinlispro
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/AdministrableProductDefinition/ap-a38f06714db0c27b2ba704652e3f08c5
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/RegulatedAuthorization/authorizationa38f06714db0c27b2ba704652e3f08c50
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/Organization/mah-3fdc76794516d7826890ab9f893e99c1
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/Organization/mapi-6f4987de7be1bbfa4ee92c07de7e94d4
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/Organization/man-e3ef26dd2c7a0847d92d3bb1a64855b9
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/PackagedProductDefinition/ppd-03a3a81da9e0b9a5bb33d75251bb5234
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/MedicinalProductDefinition/mpd33868162d255ced115cecbbf188aab4
    l: mpd33868162d255ced115cecbbf188aab4
  resource: mpd33868162d255ced115cecbbf188aab4
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/ManufacturedItemDefinition/mid-a38f06714db0c27b2ba704652e3f08c5

http://hl7.eu/fhir/ig/gravitate-health/Composition/composition-en-d33868162d255ced115cecbbf188aab4
type: Composition
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi
    l: Composition-uv-epi
language:
  v: en
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Composition composition-en-d33868162d255ced115cecbbf188aab4 Language: en Profile: Composition (ePI) identifier: https://spor.ema.europa.eu/rmswi//e21457b312eb72f9276a0c1aa36092ee status: Final type: Package Leaflet category: Raw date: 2022-02-16 13:28:17+0000 author: Organization Eli Lilly Nederland B.V. title: TEST PURPOSES ONLY - Humalog Mix50 Insulin KwikPen, 100 U/ml, Suspension for injection 3ml pre-fill Attesters - Mode Time * Official 2022-02-16 13:28:17+0000
identifier:
  system:
    v: https://spor.ema.europa.eu/rmswi/
    l: rmswi
status:
  v: final
type:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi/
      l: rmswi
    code:
      v: 100000155538
  text:
    v: Package Leaflet
category:
  coding:
    system:
      v: http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs
      l: epicategory-cs
    code:
      v: R
    display:
      v: Raw
subject:
  l: mpd33868162d255ced115cecbbf188aab4
date:
  v: 2022-02-16T13:28:17Z
title:
  v: TEST PURPOSES ONLY - Humalog Mix50 Insulin KwikPen, 100 U/ml, Suspension for injection 3ml pre-fill
attester:
  mode:
    coding:
      system:
        v: http://hl7.org/fhir/composition-attestation-mode
        l: composition-attestation-mode
      code:
        v: official
  time:
    v: 2022-02-16T13:28:17Z
section:
  title:
    v: B. Package Leaflet
  code:
    coding:
      system:
        v: https://spor.ema.europa.eu/rmswi/
        l: rmswi
      code:
        v: 100000155538
    text:
      v: B. Package Leaflet
  text:
    status:
      v: additional
    div:
      v: unavailable
  empty reason:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/list-empty-reason
        l: list-empty-reason
      code:
        v: unavailable
  section:
    title:
      v: Package leaflet: Information for the user
    code:
      text:
        v: Package leaflet: Information for the user
    text:
      status:
        v: additional
      div:
        v: PACKAGE LEAFLET: INFORMATION FOR THE USER Humalog Mix50 100 units/ml suspension for injection in cartridge insulin lispro Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
  section:
    title:
      v: What is in this leaflet
    code:
      text:
        v: What is in this leaflet
    text:
      status:
        v: additional
      div:
        v: What in this leaflet What Humalog Mix50 is and what it is used for What you need to know before you take Humalog Mix50 How to take Humalog Mix50 Possible side effects How to store Humalog Mix50 Contents of the pack and other information
  section:
    title:
      v: 1. What Humalog is and what it is used for
    code:
      text:
        v: 1. What Humalog is and what it is used for
    text:
      status:
        v: additional
      div:
        v: Humalog is used to treat diabetes. Humalog works more quickly than normal human insulin because the insulin molecule has been changed slightly. You get diabetes if your pancreas does not make enough insulin to control the level of glucose in your blood. Humalog is a substitute for your own insulin and is used to control glucose in the long term. It works very quickly and lasts a shorter time than soluble insulin (2 to 5 hours). You should normally use Humalog within 15 minutes of a meal. Your doctor may tell you to use Humalog as well as a longer-acting insulin. Each kind of insulin comes with another patient information leaflet to tell you about it. Do not change your insulin unless your doctor tells you to. Be very careful if you do change insulin. Humalog is suitable for use in adults and children.
  section:
    title:
      v: 2. What you need to know before you take Humalog
    code:
      text:
        v: 2. What you need to know before you take Humalog
    text:
      status:
        v: additional
      div:
        v: Do NOT use Humalog Mix50 if you think hypoglycaemia (low blood sugar) is starting. Further in this leaflet it tells you how to deal with mild hypoglycaemia (see Section 3: If you take more Humalog Mix50 than you need). if you are allergic to insulin lispro or any of the other ingredients of this medicine (listed in section 6). Warnings and precautions Always check the pack and the cartridge label for the name and type of the insulin when you get it from your pharmacy. Make sure you get the Humalog Mix50 that your doctor has told you to use. If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low. Warning signs are listed later in this leaflet. You must think carefully about when to have your meals, how often to exercise and how much to do. You must also keep a close watch on your blood sugar levels by testing your blood glucose often. A few people who have had hypoglycaemia after switching from animal insulin to human insulin have reported that the early warning symptoms were less obvious or different. If you often have hypoglycaemia or have difficulty recognising them, please discuss this with your doctor. If you answer YES to any of the following questions, tell your doctor, pharmacist or diabetes nurse Have you recently become ill? Do you have trouble with your kidneys or liver? Are you exercising more than usual? The amount of insulin you need may also change if you drink alcohol. You should also tell your doctor, pharmacist or diabetes nurse if you are planning to go abroad. The time difference between countries may mean that you have to have your injections and meals at different times from when you are at home. Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. Inform your doctor as soon as possible, if you experience signs…
  section:
    title:
      v: 3. How to take Humalog
    code:
      text:
        v: 3. How to take Humalog
    text:
      status:
        v: additional
      div:
        v: 3. How to use Humalog Mix50 Dose You should normally inject Humalog Mix50 within 15 minutes of a meal. If you need to, you can inject soon after a meal. But your doctor will have told you exactly how much to use, when to use it, and how often. These instructions are only for you. Follow them exactly and visit your diabetes clinic regularly. If you change the type of insulin you use (for example from a human or animal insulin to a Humalog product), you may have to take more or less than before. This might just be for the first injection or it may be a gradual change over several weeks or months. Inject Humalog Mix50 under the skin. You should not administer it using a different administration route. Under no circumstances should Humalog Mix50 be given intravenously. Preparing Humalog Mix50 Cartridges containing Humalog Mix50 should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky. If not, repeat the above procedure until contents are mixed. Cartridges contain a small glass bead to assist mixing. Do not shake vigorously as this may cause frothing which may interfere with the correct measurement of the dose. The cartridges should be examined frequently and should not be used if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance. Check each time you inject yourself. Getting the pen ready to use First wash your hands. Disinfect the rubber membrane of the cartridge. You must only use Humalog Mix50 cartridges in Lilly insulin pens. Please make sure that Humalog or Lilly cartridges are mentioned in the leaflet accompanying your pen. The 3 ml cartridge only fits the 3 ml pen. Follow the instructions that come with the pen. Put the cartridge into the pen. You will set the dose to 1 or 2 units. Then hold the pen with the needle pointing up and tap the side of the pen so that any bub…
  section:
    title:
      v: 4. Possible side effects
    code:
      text:
        v: 4. Possible side effects
    text:
      status:
        v: additional
      div:
        v: Like all medicines, this medicine can cause side effects, although not everybody gets them. Systemic allergy is rare (≥ 1/10,000 to <1/1,000). The symptoms are as follows: rash over the whole body blood pressure dropping difficulty in breathing heart beating fast wheezing sweating If you think you are having this sort of insulin allergy with Humalog, tell your doctor at once. Local allergy is common (≥ 1/100 to <1/10). Some people get redness, swelling or itching around the area of the insulin injection. This usually clears up in anything from a few days to a few weeks. If this happens to you, tell your doctor. Lipodystrophy is uncommon (≥ 1/1,000 to <1/100). If you inject insulin too often at the same place, the fatty tissue may either shrink (lipoatrophy) or thicken (lipohypertrophy). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis). The insulin may not work very well if you inject into a lumpy area. Change the injection site with each injection to help prevent these skin changes. Oedema (e.g. swelling in arms, ankles; fluid retention) has been reported, particularly at the start of insulin therapy or during a change in therapy to improve control of your blood glucose. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine. Common problems of diabetes A. Hypoglycaemia Hypoglycaemia (low blood sugar) means there is not enough sugar in the blood. This can be caused if: you take too much Humalog or other insulin; you miss or delay meals or change your diet; you exercise or work too hard just before or after a meal; you have an infection or illness (especially diarrhoea or vomiting); there is a change in your need for insul…
  section:
    title:
      v: 5. How to store Humalog
    code:
      text:
        v: 5. How to store Humalog
    text:
      status:
        v: additional
      div:
        v: Before the first use store your Humalog Mix50 in a refrigerator (2°C – 8°C). Do not freeze. Keep your cartridge in use at room temperature (below 30°C) and discard after 28 days. Do not put it near heat or in the sun. Do not keep your pen or the cartridges you are using in the fridge. The pen with the inserted cartridge should not be stored with the needle attached. Keep out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label and the carton. The expiry date refers to the last day of that month. Do not use this medicine if you notice clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance. Check each time you inject yourself. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
  section:
    title:
      v: 6. Contents of the pack and other information
    code:
      text:
        v: 6. Contents of the pack and other information
    text:
      status:
        v: additional
      div:
        v: What Humalog Mix50 100 units/ml suspension for injection in cartridge contains The active substance is insulin lispro. Insulin lispro is made in the laboratory by a ‘recombinant DNA technology’ process. It is a changed form of human insulin and so is different from other human and animal insulins. Insulin lispro is closely related to human insulin which is a natural hormone made by the pancreas. The other ingredients are protamine sulphate, m-cresol, phenol, glycerol, dibasic sodium phosphate 7H2O, zinc oxide and water for injection. Sodium hydroxide or hydrochloric acid may have been used to adjust the acidity.

ingredient-for-humalog-glycerol
type: Ingredient
id:
  v: ingredient-for-humalog-glycerol
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient ingredient-for-humalog-glycerol Profile: Ingredient (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/PDC6A3C0OX (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035 (use: official, ); status = active; manufacturedDoseForm = Suspension for injection; unitOfPresentation = Pen MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035,https://www.who-umc.org/phpid#0xF79CABF272B6A7EEF104DDDA44E82717; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription; classification = insulin lispro AdministrableProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#humalog-id; status = active; administrableDoseForm = Suspension for injection; unitOfPresentation = Pen role: Excipient Manufacturers - Manufacturer * Organization Eli Lilly and Company substance Codes - Concept * Glycerol
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: PDC6A3C0OX
status:
  v: active
for:
  l: mpd33868162d255ced115cecbbf188aab4
role:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 100000072082
    display:
      v: Excipient

ingredient-for-humalog-hydrochloricacid
type: Ingredient
id:
  v: ingredient-for-humalog-hydrochloricacid
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient ingredient-for-humalog-hydrochloricacid Profile: Ingredient (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/QTT17582CB (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035 (use: official, ); status = active; manufacturedDoseForm = Suspension for injection; unitOfPresentation = Pen MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035,https://www.who-umc.org/phpid#0xF79CABF272B6A7EEF104DDDA44E82717; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription; classification = insulin lispro AdministrableProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#humalog-id; status = active; administrableDoseForm = Suspension for injection; unitOfPresentation = Pen role: Excipient Manufacturers - Manufacturer * Organization Eli Lilly and Company substance Codes - Concept * Hydrochloric acid
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: QTT17582CB
status:
  v: active
for:
  l: mpd33868162d255ced115cecbbf188aab4
role:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 100000072082
    display:
      v: Excipient

ingredient-for-humalog-sodiumhydroxide
type: Ingredient
id:
  v: ingredient-for-humalog-sodiumhydroxide
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient ingredient-for-humalog-sodiumhydroxide Profile: Ingredient (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/55X04QC32I (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035 (use: official, ); status = active; manufacturedDoseForm = Suspension for injection; unitOfPresentation = Pen MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035,https://www.who-umc.org/phpid#0xF79CABF272B6A7EEF104DDDA44E82717; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription; classification = insulin lispro AdministrableProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#humalog-id; status = active; administrableDoseForm = Suspension for injection; unitOfPresentation = Pen role: Excipient Manufacturers - Manufacturer * Organization Eli Lilly and Company substance Codes - Concept * Sodium Hydroxide
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: 55X04QC32I
status:
  v: active
for:
  l: mpd33868162d255ced115cecbbf188aab4
role:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 100000072082
    display:
      v: Excipient

ingredient-for-humalog-sterilewaterforinjection
type: Ingredient
id:
  v: ingredient-for-humalog-sterilewaterforinjection
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient ingredient-for-humalog-sterilewaterforinjection Profile: Ingredient (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/059QF0KO0R (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035 (use: official, ); status = active; manufacturedDoseForm = Suspension for injection; unitOfPresentation = Pen MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035,https://www.who-umc.org/phpid#0xF79CABF272B6A7EEF104DDDA44E82717; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription; classification = insulin lispro AdministrableProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#humalog-id; status = active; administrableDoseForm = Suspension for injection; unitOfPresentation = Pen role: Excipient Manufacturers - Manufacturer * Organization Eli Lilly and Company substance Codes - Concept * STERILE WATER FOR INJECTION
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: 059QF0KO0R
status:
  v: active
for:
  l: mpd33868162d255ced115cecbbf188aab4
role:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 100000072082
    display:
      v: Excipient

ingredient-for-humalog-insulinlispro
type: Ingredient
id:
  v: ingredient-for-humalog-insulinlispro
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient ingredient-for-humalog-insulinlispro Profile: Ingredient (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/GFX7QIS1II (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035 (use: official, ); status = active; manufacturedDoseForm = Suspension for injection; unitOfPresentation = Pen MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035,https://www.who-umc.org/phpid#0xF79CABF272B6A7EEF104DDDA44E82717; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription; classification = insulin lispro AdministrableProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#humalog-id; status = active; administrableDoseForm = Suspension for injection; unitOfPresentation = Pen role: active Manufacturers - Manufacturer * Organization Eli Lilly and Company substance Codes - Concept * Insulin Lispro Strengths - Presentation[x] Basis * 100 U/ml (Details: UCUM codeU/ml = 'U/ml') active ingredient - basis of strength
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: GFX7QIS1II
status:
  v: active
for:
  l: mpd33868162d255ced115cecbbf188aab4
role:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 72072
    display:
      v: active
substance:
  strength:
    presentation: Quantity
      value:
        v: 100
      system:
        v: http://unitsofmeasure.org
        l: unitsofmeasure.org
      code:
        v: U/ml

ingredient-for-humalog-zincoxide
type: Ingredient
id:
  v: ingredient-for-humalog-zincoxide
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient ingredient-for-humalog-zincoxide Profile: Ingredient (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/SOI2LOH54Z (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035 (use: official, ); status = active; manufacturedDoseForm = Suspension for injection; unitOfPresentation = Pen MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035,https://www.who-umc.org/phpid#0xF79CABF272B6A7EEF104DDDA44E82717; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription; classification = insulin lispro AdministrableProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#humalog-id; status = active; administrableDoseForm = Suspension for injection; unitOfPresentation = Pen role: Excipient Manufacturers - Manufacturer * Organization Eli Lilly and Company substance Codes - Concept * Zinc Oxide
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: SOI2LOH54Z
status:
  v: active
for:
  l: mpd33868162d255ced115cecbbf188aab4
role:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 100000072082
    display:
      v: Excipient

ingredient-for-humalog-metacresol
type: Ingredient
id:
  v: ingredient-for-humalog-metacresol
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient ingredient-for-humalog-metacresol Profile: Ingredient (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/GGO4Y809LO (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035 (use: official, ); status = active; manufacturedDoseForm = Suspension for injection; unitOfPresentation = Pen MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035,https://www.who-umc.org/phpid#0xF79CABF272B6A7EEF104DDDA44E82717; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription; classification = insulin lispro AdministrableProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#humalog-id; status = active; administrableDoseForm = Suspension for injection; unitOfPresentation = Pen role: Excipient Manufacturers - Manufacturer * Organization Eli Lilly and Company substance Codes - Concept * Metacresol
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: GGO4Y809LO
status:
  v: active
for:
  l: mpd33868162d255ced115cecbbf188aab4
role:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 100000072082
    display:
      v: Excipient

ingredient-for-humalog-trometamol
type: Ingredient
id:
  v: ingredient-for-humalog-trometamol
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient ingredient-for-humalog-trometamol Profile: Ingredient (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/023C2WHX2V (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035 (use: official, ); status = active; manufacturedDoseForm = Suspension for injection; unitOfPresentation = Pen MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035,https://www.who-umc.org/phpid#0xF79CABF272B6A7EEF104DDDA44E82717; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription; classification = insulin lispro AdministrableProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#humalog-id; status = active; administrableDoseForm = Suspension for injection; unitOfPresentation = Pen role: Excipient Manufacturers - Manufacturer * Organization Eli Lilly and Company substance Codes - Concept * Trometamol
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: 023C2WHX2V
status:
  v: active
for:
  l: mpd33868162d255ced115cecbbf188aab4
role:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 100000072082
    display:
      v: Excipient

substance-insulinlispro
type: SubstanceDefinition
id:
  v: substance-insulinlispro
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/SubstanceDefinition-uv-epi
    l: SubstanceDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: SubstanceDefinition substance-insulinlispro Profile: SubstanceDefinition (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta//GFX7QIS1II (use: official, ) version: 1 status: Active manufacturer: Organization Eli Lilly Nederland B.V. Structures - MolecularFormula * C257H382O75N65S6 Names - Name * 28(SUP B)-L-LYSINE-29(SUP B)-L-PROLINEINSULIN (HUMAN)
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta/
    l: beta
  value:
    v: GFX7QIS1II
version:
  v: 1
status:
  coding:
    system:
      v: http://hl7.org/fhir/publication-status
      l: publication-status
    code:
      v: active
structure:
  molecular formula:
    v: C257H382O75N65S6
name:
  name:
    v: 28(SUP B)-L-LYSINE-29(SUP B)-L-PROLINEINSULIN (HUMAN)

http://hl7.eu/fhir/ig/gravitate-health/AdministrableProductDefinition/ap-a38f06714db0c27b2ba704652e3f08c5
type: AdministrableProductDefinition
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/AdministrableProductDefinition-uv-epi
    l: AdministrableProductDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: AdministrableProductDefinition ap-a38f06714db0c27b2ba704652e3f08c5 Profile: AdministrableProductDefinition (ePI) identifier: https://spor.ema.europa.eu/pmswi/humalog-id status: Active formOf: MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035,https://www.who-umc.org/phpid#0xF79CABF272B6A7EEF104DDDA44E82717; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription; classification = insulin lispro administrableDoseForm: Suspension for injection unitOfPresentation: Pen producedFrom: ManufacturedItemDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035 (use: official, ); status = active; manufacturedDoseForm = Suspension for injection; unitOfPresentation = Pen routeOfAdministration code: Subcutaneous use TargetSpecies - Code * Human
identifier:
  system:
    v: https://spor.ema.europa.eu/pmswi
    l: pmswi
  value:
    v: humalog-id
status:
  v: active
form of:
  l: mpd33868162d255ced115cecbbf188aab4
administrable dose form:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 100000073864
    display:
      v: Suspension for injection
unit of presentation:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 200000002135
    display:
      v: Pen
route of administration:
  code:
    coding:
      system:
        v: https://spor.ema.europa.eu/rmswi
        l: rmswi
      code:
        v: 100000073633
      display:
        v: Subcutaneous use

http://hl7.eu/fhir/ig/gravitate-health/RegulatedAuthorization/authorizationa38f06714db0c27b2ba704652e3f08c50
type: RegulatedAuthorization
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/RegulatedAuthorization-uv-epi
    l: RegulatedAuthorization-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: RegulatedAuthorization authorizationa38f06714db0c27b2ba704652e3f08c50 Profile: RegulatedAuthorization (ePI) identifier: https://spor.ema.europa.eu/pmswi/EU/1/96/007/035 (use: official, ) subject: MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035,https://www.who-umc.org/phpid#0xF79CABF272B6A7EEF104DDDA44E82717; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription; classification = insulin lispro type: Marketing Authorisation status: Active statusDate: 2015-02-07 13:28:17+0000 holder: Organization Eli Lilly Nederland B.V.
identifier:
  use:
    v: official
  system:
    v: https://spor.ema.europa.eu/pmswi
    l: pmswi
  value:
    v: EU/1/96/007/035
subject:
  l: mpd33868162d255ced115cecbbf188aab4
type:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 100000072062
    display:
      v: Marketing Authorisation
status:
  coding:
    system:
      v: http://hl7.org/fhir/publication-status
      l: publication-status
    code:
      v: active
    display:
      v: Active
status date:
  v: 2015-02-07T13:28:17Z

http://hl7.eu/fhir/ig/gravitate-health/Organization/mah-3fdc76794516d7826890ab9f893e99c1
type: Organization
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi
    l: Organization-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Organization mah-3fdc76794516d7826890ab9f893e99c1 Profile: Organization (ePI) identifier: https://spor.ema.europa.eu/omswi/ORG-100000426 (use: official, ) active: true type: Marketing authorisation holder name: Eli Lilly Nederland B.V. Contacts - Address * Papendorpseweg 83, 3528 BJ Utrecht NL(work)
identifier:
  use:
    v: official
  system:
    v: https://spor.ema.europa.eu/omswi
    l: omswi
  value:
    v: ORG-100000426
active:
  v: true
type:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 220000000034
    display:
      v: Marketing authorisation holder
name:
  v: Eli Lilly Nederland B.V.
contact:
  address:
    use:
      v: work
    type:
      v: physical
    text:
      v: Papendorpseweg 83, 3528 BJ Utrecht NL
    line:
      v: Papendorpseweg 83, 3528 BJ
    city:
      v: Utrecht
    country:
      v: NL

http://hl7.eu/fhir/ig/gravitate-health/Organization/mapi-6f4987de7be1bbfa4ee92c07de7e94d4
type: Organization
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi
    l: Organization-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Organization mapi-6f4987de7be1bbfa4ee92c07de7e94d4 Profile: Organization (ePI) identifier: https://spor.ema.europa.eu/omswi/ORG-100000156 (use: official, ) active: true type: Manufacturer name: Eli Lilly and Company Contacts - Address * Lilly Technology Center Building 333 and 324, Indianapolis, Indiana, USA Indianapolis US(work)
identifier:
  use:
    v: official
  system:
    v: https://spor.ema.europa.eu/omswi
    l: omswi
  value:
    v: ORG-100000156
active:
  v: true
type:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 220000000033
    display:
      v: Manufacturer
name:
  v: Eli Lilly and Company
contact:
  address:
    use:
      v: work
    type:
      v: physical
    text:
      v: Lilly Technology Center Building 333 and 324, Indianapolis, Indiana, USA Indianapolis US
    line:
      v: Lilly Technology Center Building 333 and 324, Indianapolis, Indiana, USA
    city:
      v: Indianapolis
    country:
      v: US

http://hl7.eu/fhir/ig/gravitate-health/Organization/man-e3ef26dd2c7a0847d92d3bb1a64855b9
type: Organization
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi
    l: Organization-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Organization man-e3ef26dd2c7a0847d92d3bb1a64855b9 Profile: Organization (ePI) identifier: https://spor.ema.europa.eu/omswi/ORG-100003996 (use: official, ) active: true type: Manufacturer name: Lilly S.A. Contacts - Address * Avenida de la Industria 30, 28108 Alcobendas, Madrid, Spain Alcobendas ES(work)
identifier:
  use:
    v: official
  system:
    v: https://spor.ema.europa.eu/omswi
    l: omswi
  value:
    v: ORG-100003996
active:
  v: true
type:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 220000000033
    display:
      v: Manufacturer
name:
  v: Lilly S.A.
contact:
  address:
    use:
      v: work
    type:
      v: physical
    text:
      v: Avenida de la Industria 30, 28108 Alcobendas, Madrid, Spain Alcobendas ES
    line:
      v: Avenida de la Industria 30, 28108 Alcobendas, Madrid, Spain
    city:
      v: Alcobendas
    country:
      v: ES

http://hl7.eu/fhir/ig/gravitate-health/PackagedProductDefinition/ppd-03a3a81da9e0b9a5bb33d75251bb5234
type: PackagedProductDefinition
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/PackagedProductDefinition-uv-epi
    l: PackagedProductDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: PackagedProductDefinition ppd-03a3a81da9e0b9a5bb33d75251bb5234 Profile: PackagedProductDefinition (ePI) identifier: https://spor.ema.europa.eu/pmswi/EU/1/96/007/035 (use: official, ) name: Humalog Mix50 Insulin KwikPen, 100 U/ml, Suspension for injection 3ml pre-fill 5 type: Chemical Medicinal Prodcut packageFor: MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035,https://www.who-umc.org/phpid#0xF79CABF272B6A7EEF104DDDA44E82717; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription; classification = insulin lispro status: Active statusDate: 2015-02-07 13:28:17+0000 containedItemQuantity: 3 ml (Details: UCUM codeml = 'ml') manufacturer: Organization Lilly S.A. packaging type: Box quantity: 1 material: Cardboard packaging identifier: https://spor.ema.europa.eu/pmswi/123456 type: Pre-filled pen quantity: 5 material: Glass type 1 containedItem Items - Reference * ManufacturedItemDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/96/007/035 (use: official, ); status = active; manufacturedDoseForm = Suspension for injection; unitOfPresentation = Pen
identifier:
  use:
    v: official
  system:
    v: https://spor.ema.europa.eu/pmswi
    l: pmswi
  value:
    v: EU/1/96/007/035
name:
  v: Humalog Mix50 Insulin KwikPen, 100 U/ml, Suspension for injection 3ml pre-fill 5
type:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 100000155527
    display:
      v: Chemical Medicinal Prodcut
package for:
  l: mpd33868162d255ced115cecbbf188aab4
status:
  coding:
    system:
      v: http://hl7.org/fhir/publication-status
      l: publication-status
    code:
      v: active
    display:
      v: Active
status date:
  v: 2015-02-07T13:28:17Z
contained item quantity:
  value:
    v: 3
  system:
    v: http://unitsofmeasure.org
    l: unitsofmeasure.org
  code:
    v: ml
packaging:
  type:
    coding:
      system:
        v: https://spor.ema.europa.eu/rmswi
        l: rmswi
      code:
        v: 100000073498
      display:
        v: Box
  quantity:
    v: 1
  material:
    coding:
      system:
        v: https://spor.ema.europa.eu/rmswi
        l: rmswi
      code:
        v: 200000003529
      display:
        v: Cardboard
  packaging:
    identifier:
      system:
        v: https://spor.ema.europa.eu/pmswi
        l: pmswi
      value:
        v: 123456
    quantity:
      v: 5

mpd33868162d255ced115cecbbf188aab4
type: MedicinalProductDefinition
id:
  v: mpd33868162d255ced115cecbbf188aab4
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi
    l: MedicinalProductDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: MedicinalProductDefinition mpd33868162d255ced115cecbbf188aab4 Profile: MedicinalProductDefinition (ePI) identifier: https://spor.ema.europa.eu/pmswi/EU/1/96/007/035, https://www.who-umc.org/phpid/0xF79CABF272B6A7EEF104DDDA44E82717 type: Medicinal Product domain: Human use status: active legalStatusOfSupply: Medicinal product subject to medical prescription classification: insulin lispro name productName: Humalog Mix50 Insulin KwikPen, 100 U/ml, Suspension for injection 3ml pre-fill type: Full name part part: Humalog type: Invented name part part part: insulin lispro type: Scientific name part part part: 100 U/ml type: Strength part part part: Suspension for injection type: Pharmaceutical dose form part Usages - Country Jurisdiction Language * Denmark Denmark English
identifier:
  system:
    v: https://spor.ema.europa.eu/pmswi
    l: pmswi
  value:
    v: EU/1/96/007/035
identifier:
  system:
    v: https://www.who-umc.org/phpid
    l: phpid
  value:
    v: 0xF79CABF272B6A7EEF104DDDA44E82717
type:
  coding:
    system:
      v: http://hl7.org/fhir/medicinal-product-type
      l: medicinal-product-type
    code:
      v: MedicinalProduct
    display:
      v: Medicinal Product
domain:
  coding:
    system:
      v: http://hl7.org/fhir/medicinal-product-domain
      l: medicinal-product-domain
    code:
      v: Human
    display:
      v: Human use
status:
  coding:
    system:
      v: http://hl7.org/fhir/publication-status
      l: publication-status
    code:
      v: active
    display:
      v: active
legal status of supply:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 100000072084
    display:
      v: Medicinal product subject to medical prescription
classification:
  coding:
    system:
      v: http://www.whocc.no/atc
      l: atc
    code:
      v: A10AB04
    display:
      v: insulin lispro
name:
  product name:
    v: Humalog Mix50 Insulin KwikPen, 100 U/ml, Suspension for injection 3ml pre-fill
  type:
    coding:
      system:
        v: https://spor.ema.europa.eu/lists/220000000000
        l: https://spor.ema.europa.eu/lists/220000000000
      code:
        v: 220000000001
      display:
        v: Full name
  part:
    part:
      v: Humalog
  part:
    part:
      v: insulin lispro
  part:
    part:
      v: 100 U/ml
  part:
    part:
      v: Suspension for injection

http://hl7.eu/fhir/ig/gravitate-health/ManufacturedItemDefinition/mid-a38f06714db0c27b2ba704652e3f08c5
type: ManufacturedItemDefinition
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ManufacturedItemDefinition-uv-epi
    l: ManufacturedItemDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ManufacturedItemDefinition mid-a38f06714db0c27b2ba704652e3f08c5 Profile: ManufacturedItemDefinition (ePI) identifier: https://spor.ema.europa.eu/pmswi/EU/1/96/007/035 (use: official, ) status: Active manufacturedDoseForm: Suspension for injection unitOfPresentation: Pen manufacturer: Organization Lilly S.A.
identifier:
  use:
    v: official
  system:
    v: https://spor.ema.europa.eu/pmswi
    l: pmswi
  value:
    v: EU/1/96/007/035
status:
  v: active
manufactured dose form:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi/
      l: rmswi
    code:
      v: 100000073864
    display:
      v: Suspension for injection
unit of presentation:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 200000002135
    display:
      v: Pen

v: 100000155538

v: 100000155538

v: 100000155538

v: 100000155538

v: 100000155538

v: 100000155538

v: 100000155538

v: 100000155538

v: PDC6A3C0OX

v: Glycerol

v: QTT17582CB

v: Hydrochloric acid

v: 55X04QC32I

v: Sodium Hydroxide

v: 059QF0KO0R

v: STERILE WATER FOR INJECTION

v: GFX7QIS1II

v: Insulin Lispro

v: ACTIB

v: active ingredient - basis of strength

v: SOI2LOH54Z

v: Zinc Oxide

v: GGO4Y809LO

v: Metacresol

v: 023C2WHX2V

v: Trometamol

v: 100000109093

v: Human

v: 100000073543

v: Pre-filled pen

v: 200000003204

v: Glass type 1

v: 220000000002

v: Invented name part

v: 220000000003

v: Scientific name part

v: 220000000004

v: Strength part

v: 220000000005

v: Pharmaceutical dose form part

v: urn:iso:std:iso:3166
l: 3166

v: DK

v: Denmark

v: urn:iso:std:iso:3166
l: 3166

v: DK

v: Denmark

v: urn:ietf:bcp:47
l: 47

v: en

v: English